Madhusmita Behera
A5012015166- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Neuroendocrine Tumor Research Advances
- Genetic factors in colorectal cancer
- Histone Deacetylase Inhibitors Research
- Pancreatic and Hepatic Oncology Research
- Radiomics and Machine Learning in Medical Imaging
- Epigenetics and DNA Methylation
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- PI3K/AKT/mTOR signaling in cancer
- Intermetallics and Advanced Alloy Properties
- Cancer Diagnosis and Treatment
- Multiple and Secondary Primary Cancers
- Head and Neck Cancer Studies
- RNA modifications and cancer
- Global Cancer Incidence and Screening
- Cancer-related gene regulation
- Cancer-related Molecular Pathways
Emory University
2015-2024
Technology Applications (United States)
2023
Woodruff Health Sciences Center
2022-2023
KIIT University
2023
The Wallace H. Coulter Department of Biomedical Engineering
2023
Winship Cancer Institute
2013-2022
Ashoka University
2022
University of Pennsylvania
2022
Piedmont Cancer Institute
2014-2022
Institute of Minerals and Materials Technology
2021-2022
<h2>Summary</h2> Papillary thyroid carcinoma (PTC) is the most common type of cancer. Here, we describe genomic landscape 496 PTCs. We observed a low frequency somatic alterations (relative to other carcinomas) and extended set known PTC driver include <i>EIF1AX</i>, <i>PPM1D</i>, <i>CHEK2</i> diverse gene fusions. These discoveries reduced fraction cases with unknown oncogenic from 25% 3.5%. Combined analyses variants, expression, methylation demonstrated that different groups lead...
Significance Therapies that harness the immune system have recently been approved for cancer treatment. Identification of biomarkers to monitor or predict patients’ responses immunotherapies would help guide treatment decisions. Herein we analyzed changes in peripheral blood T cells from lung patients receiving immunotherapy blocking PD-1 inhibitory pathway. We detected CD8 T-cell following most patients. In addition, our data suggest an increase proliferation PD-1+ within 4 wk initiation...
Highlights•Multi-omics definition of four robust molecular TET subtypes associated with survival•Thymomas have the lowest mutational burden among adult cancers•Enrichment HRAS, NRAS, TP53, and recurrent GTF2I mutations are observed•Expression autoimmune targets aneuploidy links thymoma to myasthenia gravisSummaryThymic epithelial tumors (TETs) one rarest malignancies. Among TETs, is most predominant, characterized by a unique association diseases, followed thymic carcinoma, which less common...
Human epidermal growth factor receptor 2 (HER2) mutations have been reported in lung adenocarcinomas. Herein, the authors describe prevalence, clinical features, and outcomes associated with HER2 1007 patients Lung Cancer Mutation Consortium (LCMC).Patients advanced-stage adenocarcinomas were enrolled to LCMC. Tumor specimens assessed for diagnosis adequacy; multiplexed genotyping was performed Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories examine 10 oncogenic...
Small-cell lung cancer (SCLC) patients unresponsive or relapsing within 90 days after frontline chemotherapy have poor prognosis and are treated with regimens different from the first-line regimen. Potential differences in efficacy of second-line therapy for refractory sensitive SCLC not been well studied.
To analyze outcomes and predictors associated with proton radiation therapy for non-small cell lung cancer (NSCLC) in the National Cancer Database.The Database was queried to capture patients stage I-IV NSCLC treated thoracic from 2004 2012. A logistic regression model used determine utilization of therapy. The univariate multivariable association overall survival were assessed by Cox proportional hazards models along log-rank tests. propensity score matching method implemented balance...
BACKGROUND The discovery of oncogenic drivers has ushered in a new era for lung cancer, but the role these mutations different racial/ethnic minorities been understudied. Lung Cancer Mutation Consortium 1 (LCMC1) database was investigated to evaluate frequency and impact adenocarcinomas minority patient population. METHODS Patients with metastatic from 14 US sites were enrolled LCMC1. Tumor samples collected 2009 through 2012 multiplex genotyping performed on 10 ( KRAS , epidermal growth...
Abstract Ribonucleotide reductase (RNR) catalyzes the de novo synthesis of deoxyribonucleoside diphosphates (dNDPs) to provide dNTP precursors for DNA synthesis. Here, we report that acetylation and deacetylation RRM2 subunit RNR acts as a molecular switch impacts activity, synthesis, replication fork progression. Acetylation at K95 abrogates activity by disrupting its homodimer assembly. is directly acetylated KAT7, deacetylated Sirt2, respectively. which level peak in S phase, sustains or...
IntroductionLung cancer survival is improving in the United States. We investigated whether there was a similar trend within Veterans Health Administration (VHA), largest integrated healthcare system States.MethodsData from Affairs Central Cancer Registry (VACCR) were analyzed for temporal trends using Kaplan-Meier (K-M) estimates and linear regression.Results54,922 identified with lung diagnosed 2010-2017. Histologies classified as non-small cell (NSCLC) (64.2%), small (SCLC) (12.9%),...
High-grade neuroendocrine carcinomas are rare in the gastrointestinal tract. However, treatment patterns and outcomes have not been well described.The National Cancer Database was analyzed. The primary objective to describe clinical identify prognostic factors. Univariate multivariate analyses were done factors associated with patient outcome.A total of 1,861 patients identified between 2004 2013. mean age 63 years (standard deviation ±13). majority (78.1%) non-Hispanic whites. most common...
Acquired resistance is inevitable in non–small cell lung cancers (NSCLCs) treated with osimertinib (OSI), and the mechanisms are not well defined. The MERTK ligand GAS6 promoted downstream oncogenic signaling EGFR-mutated (EGFRMT) NSCLC cells OSI, suggesting a role for activation OSI resistance. Indeed, treatment MRX-2843, first-in-class kinase inhibitor, resensitized GAS6-treated to OSI. Both EGF stimulated PI3K/AKT MAPK/ERK parental cells, but only activated these pathways OSI-resistant...
Loss of LKB1 activity is prevalent in KRAS mutant lung adenocarcinoma and promotes aggressive treatment-resistant tumors. Previous studies have shown that a negative regulator the focal adhesion kinase (FAK), but vivo testing efficacy FAK inhibition cancers are lacking. Here, we took pharmacologic approach to show an effective early-treatment strategy for this high-risk molecular subtype. We established lenti-Cre-induced Kras Lkb1 genetically engineered mouse model (KLLenti) develops 100%...